|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for JAK2 |
 Gene summary |
| Basic gene Info. | Gene symbol | JAK2 |
| Gene name | Janus kinase 2 | |
| Synonyms | JTK10|THCYT3 | |
| Cytomap | UCSC genome browser: 9p24 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004972.3, | |
| Description | JAK-2Janus kinase 2 (a protein tyrosine kinase)tyrosine-protein kinase JAK2 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 147796 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000096968 | ||
| HPRD : 00993 | ||
| Vega : OTTHUMG00000019490 | ||
| Protein | UniProt: O60674 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_JAK2 | |
| BioGPS: 3717 | ||
| Pathway | NCI Pathway Interaction Database: JAK2 | |
| KEGG: JAK2 | ||
| REACTOME: JAK2 | ||
| Pathway Commons: JAK2 | ||
| Context | iHOP: JAK2 | |
| ligand binding site mutation search in PubMed: JAK2 | ||
| UCL Cancer Institute: JAK2 | ||
| Assigned class in mutLBSgeneDB | A: This gene has a literature evidence and it belongs to targetable_mutLBSgenes. | |
| References showing study about ligand binding site mutation for JAK2. | 1. Staerk, J., Kallin, A., Royer, Y., Diaconu, C. C., Dusa, A., Demoulin, J. B., ... & Constantinescu, S. N. (2007). JAK2, the JAK2 V617F mutant and cytokine receptors. Pathologie Biologie, 55(2), 88-91. 16904848 | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0010811 | positive regulation of cell-substrate adhesion | 10925297 | GO:0019221 | cytokine-mediated signaling pathway | 8609418 | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 8609418 | GO:0034612 | response to tumor necrosis factor | 8609418 | GO:0035409 | histone H3-Y41 phosphorylation | 19783980 | GO:0035722 | interleukin-12-mediated signaling pathway | 7528775 | GO:0046677 | response to antibiotic | 16280321 | GO:0050727 | regulation of inflammatory response | 10925297 | GO:0060396 | growth hormone receptor signaling pathway | 10925297 | GO:0070671 | response to interleukin-12 | 7528775 |
| Top |
| Ligand binding site mutations for JAK2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | L680 | I682T | COAD | 2 | Q626 | L624P | COAD | 1 | E627 | E627D | COAD | 1 | E627 | E627K | COAD | 1 | E627 | E627G | COAD | 1 | T555,T557 | F556L | KIRC | 1 | I992 | V990L | LUSC | 1 | L579 | L579P | OV | 1 | I559 | F560S | SKCM | 1 | G858 | G858S | STAD | 1 | V911 | V911A | UCEC | 1 | L579 | L579I | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Clinical information for JAK2 from My Cancer Genome. |
| Janus kinase 2 (JAK2) encodes for a protein tyrosine kinase involved in cytokine receptor signaling. Mutations in JAK2 have been identified in ALL and other hematologic malignancies.Preclinical models have been used to test efficacy of mTOR and JAK inhibitors in CRLF2-rearranged and JAK2-mutated high-risk precursor B-cell ALL (Maude et al. 2011).Related Pathways: JAK/STAT signaling Brown, V., Borinstein, S.C., Friedman, D. 2015. JAK2. My Cancer Genomehttps://www.mycancergenome.org/content/gene/jak2/ (Updated December 2015) |
| Top |
| Protein structure related information for JAK2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | I559 | F560S | -1.8749616 | Q626 | L624P | -1.5247625 | V911 | V911A | -1.4770057 | E627 | E627G | -1.3364482 | L579 | L579P | -1.2791344 | E627 | E627K | -1.1898952 | L680 | I682T | -1.1674434 | E627 | E627D | -1.155858 | L579 | L579I | -1.1107339 | I992 | V990L | -0.86816967 | G858 | G858S | -0.5728761 | T557 | F556L | -0.42502214 | T555 | F556L | -0.42502214 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for JAK2 from PDB |
| PDB ID | PDB title | PDB structure | 2B7A | The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor |  |
| Top |
| Differential gene expression and gene-gene network for JAK2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for JAK2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0032463 | Polycythemia Vera | 341 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C0027022 | Myeloproliferative Disorders | 274 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C0040028 | Thrombocythemia, Essential | 266 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C0001815 | Primary Myelofibrosis | 242 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C0836924 | Thrombocytosis | 44 | Biomarker, GeneticVariation |
| umls:C0023467 | Leukemia, Myeloid, Acute | 41 | Biomarker, GeneticVariation, PostTranslationalModification |
| umls:C0032461 | Polycythemia | 41 | Biomarker, GeneticVariation |
| umls:C0023418 | Leukemia | 30 | Biomarker, GeneticVariation |
| umls:C0856761 | Budd-Chiari Syndrome | 17 | Biomarker, GeneticVariation |
| umls:C0042487 | Venous Thrombosis | 16 | Biomarker, GeneticVariation |
| umls:C0009324 | Colitis, Ulcerative | 11 | Biomarker, GeneticVariation |
| umls:C0040038 | Thromboembolism | 7 | Biomarker, GeneticVariation |
| umls:C0032962 | Pregnancy Complications | 3 | Biomarker, GeneticVariation |
| umls:C0151744 | Myocardial Ischemia | 3 | Biomarker, GeneticVariation |
| umls:C0000786 | Abortion, Spontaneous | 1 | Biomarker |
| umls:C0006663 | Calcinosis | 1 | Biomarker |
| umls:C0018824 | Heart Valve Diseases | 1 | Biomarker |
| umls:C0025472 | Mesenteric Vascular Occlusion | 1 | Biomarker |
| umls:C0033578 | Prostatic Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for JAK2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB04716 | 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE | Small molecule |  |
| Investigational | DB05243 | XL019 | Small molecule |  |
| Experimental | DB07161 | 5-phenyl-1H-indazol-3-amine | Small molecule |  |
| Experimental | DB07162 | 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide | Small molecule |  |
| Experimental | DB08067 | 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM | Small molecule |  |
| Experimental | DB08183 | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile | Small molecule |  |
| Approved | DB08877 | Ruxolitinib | Small molecule |  |
| Approved|investigational | DB08895 | Tofacitinib | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of JAK2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MI1 | CP-690,550 | 3fup | A | G858 | 1P5 | (3S)-1-[6-(2-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-3-YL)PYRIMIDIN-4-YL]-N,N-DIETHYLPIPERIDINE-3-CARBOXAMIDE | 3io7 | A | G858 | DQX | 8-[3,5-DIFLUORO-4-(MORPHOLIN-4-YLMETHYL)PHENYL]-2-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)QUINOXALINE | 3krr | A | G858 | 0TP | 4-AMINO-N-METHYL-2-[4-(MORPHOLIN-4-YL)PHENYL]THIENO[3,2-C]PYRIDINE-7-CARBOXAMIDE | 3tjc | A | G858 | 0TP | 4-AMINO-N-METHYL-2-[4-(MORPHOLIN-4-YL)PHENYL]THIENO[3,2-C]PYRIDINE-7-CARBOXAMIDE | 3tjc | B | G858 | 6TP | 4-AMINO-2-[4-(TERT-BUTYLSULFAMOYL)PHENYL]-N-METHYLTHIENO[3,2-C]PYRIDINE-7-CARBOXAMIDE | 3tjd | B | G858 | O19 | (2R)-N-[4-[2-[(4-MORPHOLIN-4-YLPHENYL)AMINO] PYRIMIDIN-4-YL]PHENYL]PYRROLIDINE-2- CARBOXAMIDE | 4bbf | A | G858 | O19 | (2R)-N-[4-[2-[(4-MORPHOLIN-4-YLPHENYL)AMINO] PYRIMIDIN-4-YL]PHENYL]PYRROLIDINE-2- CARBOXAMIDE | 4bbf | B | G858 | O19 | (2R)-N-[4-[2-[(4-MORPHOLIN-4-YLPHENYL)AMINO] PYRIMIDIN-4-YL]PHENYL]PYRROLIDINE-2- CARBOXAMIDE | 4bbf | C | G858 | O19 | (2R)-N-[4-[2-[(4-MORPHOLIN-4-YLPHENYL)AMINO] PYRIMIDIN-4-YL]PHENYL]PYRROLIDINE-2- CARBOXAMIDE | 4bbf | D | G858 | 0NH | 1-[4-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL]-1,6- DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE | 4e4m | A | G858 | 0NH | 1-[4-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL]-1,6- DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE | 4e4m | B | G858 | 0NH | 1-[4-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL]-1,6- DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE | 4e4m | D | G858 | 0NH | 1-[4-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL]-1,6- DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE | 4e4m | E | G858 | 0NU | 3-[(3R)-3-(IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(6H)- YL)PIPERIDIN-1-YL]-3-OXOPROPANENITRILE | 4e6d | A | G858 | 0NV | 1-(1-BENZYLPIPERIDIN-4-YL)-1,6-DIHYDROIMIDAZO[4,5- D]PYRROLO[2,3-B]PYRIDINE | 4e6q | A | G858 | 15V | N-[1-(3-CHLOROPHENYL)-3-METHYL-1H-PYRAZOL-5- YL]PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE | 4hge | A | G858 | 15V | N-[1-(3-CHLOROPHENYL)-3-METHYL-1H-PYRAZOL-5- YL]PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE | 4hge | B | G858 | VVQ | 5-(2-AMINOPYRIMIDIN-4-YL)-2-(5-CHLORO-2- METHYLPHENYL)-1H-PYRROLE-3-CARBOXAMIDE | 4d0w | A | G858 | 953 | 5-(2-AMINOPYRIMIDIN-4-YL)-2-[2-CHLORO-5- (TRIFLUOROMETHYL)PHENYL]-1H-PYRROLE-3- CARBOXAMIDE | 4d0x | A | G858 | BJG | 2-(5-CHLORO-2-METHYLPHENYL)-1-METHYL-5-(2- {[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]AMINO} PYRIMIDIN-4-YL)-1H-PYRROLE-3-CARBOXAMIDE | 4d1s | A | G858 | 50Y | N,N-DICYCLOPROPYL-6-ETHYL-4-[(3-METHOXYPROPYL)AMINO]-1- METHYL-1,6-DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3- B]PYRIDINE-7-CARBOXAMIDE | 5cf4 | A | G858 | 50W | N,N-DICYCLOPROPYL-4-[(4,5-DIMETHYL-1,3-THIAZOL-2-YL) AMINO]-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5- D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE | 5cf5 | A | G858 | 50O | N,N-DICYCLOPROPYL-6-[(2S)-2,3-DIHYDROXYPROPYL]-1- METHYL-4-(METHYLAMINO)-1,6-DIHYDROIMIDAZO[4,5- D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE | 5cf6 | B | G858 | 50V | N,N-DICYCLOPROPYL-4-[(1,5-DIMETHYL-1H-PYRAZOL-3-YL) AMINO]-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5- D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE | 5cf8 | A | G858 | MI1 | CP-690,550 | 3fup | B | G858 V911 | NVB | N-METHYL-4-[3-(3,4,5-TRIMETHOXYPHENYL)QUINOXALIN-5-YL]BENZENESULFONAMIDE | 3lpb | A | G858 V911 | 88A | 8-(4-METHYLSULFONYLPHENYL)-N-(4-MORPHOLIN-4-YLPHENYL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE | 4aqc | A | G858 V911 | 88A | 8-(4-METHYLSULFONYLPHENYL)-N-(4-MORPHOLIN-4-YLPHENYL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE | 4aqc | B | G858 V911 | 0NU | 3-[(3R)-3-(IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(6H)- YL)PIPERIDIN-1-YL]-3-OXOPROPANENITRILE | 4e6d | B | G858 V911 | 0NV | 1-(1-BENZYLPIPERIDIN-4-YL)-1,6-DIHYDROIMIDAZO[4,5- D]PYRROLO[2,3-B]PYRIDINE | 4e6q | B | G858 V911 | 1M3 | N-TERT-BUTYL-3-[(5-METHYL-2-{[4-(4-METHYLPIPERAZIN-1- YL)PHENYL]AMINO}PYRIMIDIN-4-YL) AMINO]BENZENESULFONAMIDE | 4ji9 | A | G858 V911 | 1M3 | N-TERT-BUTYL-3-[(5-METHYL-2-{[4-(4-METHYLPIPERAZIN-1- YL)PHENYL]AMINO}PYRIMIDIN-4-YL) AMINO]BENZENESULFONAMIDE | 4ji9 | B | G858 V911 | 2HB | G146034 | N-(5-{4-[(1,1-DIOXIDOTHIOMORPHOLIN-4-YL) METHYL]PHENYL}[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL) CYCLOPROPANECARBOXAMIDE | 4p7e | B | G858 V911 | QUP | 1-(5-CHLORO-2-METHYLPHENYL)-4-(PYRROLO[2,1-F] [1,2,4]TRIAZIN-4-YL)-1H-PYRROLE-2- CARBOXAMIDE | 5aep | A | G858 V911 | ATP | ATP | 4fvq | A | T555 T557 I559 L579 Q626 E627 L680 | ATP | ATP | 4fvr | A | T555 T557 I559 L579 Q626 E627 L680 | JZH | (3S)-3-(4-HYDROXYPHENYL)-1,5-DIHYDRO-1,5,12-TRIAZABENZO[4,5]CYCLOOCTA[1,2,3-CD]INDEN-4(3H)-ONE | 3jy9 | A | V911 | 3KC | 3-CHLORO-4-(4H-3,4,7-TRIAZADIBENZO[CD,F]AZULEN-6-YL)PHENOL | 3kck | A | V911 | NVB | N-METHYL-4-[3-(3,4,5-TRIMETHOXYPHENYL)QUINOXALIN-5-YL]BENZENESULFONAMIDE | 3lpb | B | V911 | 17P | 1-(CYCLOHEXYLAMINO)-7-(1-METHYL-1H-PYRAZOL-4-YL)-5H-PYRIDO[4,3-B]INDOLE-4-CARBOXAMIDE | 3rvg | A | V911 | 0X2 | 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE | 4gfm | A | V911 | 1K3 | 5-(4-METHOXYPHENYL)-N-[4-(4-METHYLPIPERAZIN-1-YL) PHENYL][1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE | 4jia | A | V911 | 2HB | G146034 | N-(5-{4-[(1,1-DIOXIDOTHIOMORPHOLIN-4-YL) METHYL]PHENYL}[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL) CYCLOPROPANECARBOXAMIDE | 4p7e | A | V911 | 4HW | N~3~-PHENYL-1-[6-(PHENYLAMINO)PYRIMIDIN-4-YL]-1H-1,2,4- TRIAZOLE-3,5-DIAMINE | 4ytc | A | V911 | VJK | DECERNOTINIB, ADELATINIB, VX-509 | (2R)-2-METHYL-2-[[2-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL) PYRIMIDIN-4-YL]AMINO]-N-[2,2,2-TRIS(FLUORANYL) ETHYL]BUTANAMIDE | 4yti | A | V911 | 046 | 5-{[6-(ACETYLAMINO)PYRIMIDIN-4-YL]OXY}-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}-1H-INDOLE-1-CARBOXAMIDE | 3ugc | A | V911 I992 |
| Top |
| Conservation information for LBS of JAK2 |
| Multiple alignments for O60674 in multiple species |
| LBS | AA sequence | # species | Species | A880 | TGEVVAVKKLQ | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D939 | YGSLRDYLQKH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D994 | RVKIGDFGLTK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E627 | NILVQEFVKFG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E898 | RDFEREIEILK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E930 | LRLIMEYLPYG | 2 | Mus musculus, Rattus norvegicus | E930 | LKLIMEYLPYG | 1 | Homo sapiens | F628 | ILVQEFVKFGS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F860 | LGKGNFGSVEM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F995 | VKIGDFGLTKV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G554 | ESLGQGTFTKI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G856 | FLQQLGKGNFG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G858 | QQLGKGNFGSV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G861 | GKGNFGSVEMC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G935 | EYLPYGSLRDY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G993 | NRVKIGDFGLT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H974 | TKRYIHRDLAT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I559 | GTFTKIFKGVR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I910 | LQHDNIVKYKG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I973 | GTKRYIHRDLA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I982 | LATRNILVENE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I992 | ENRVKIGDFGL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K581 | TEVLLKVLDKA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K677 | GNVCAKNILLI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K857 | LQQLGKGNFGS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K882 | EVVAVKKLQHS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K943 | RDYLQKHKERI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L551 | IFNESLGQGTF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L579 | HETEVLLKVLD | 2 | Homo sapiens, Rattus norvegicus | L579 | HKTEVLLKVLD | 1 | Mus musculus | L680 | CAKNILLIREE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L855 | KFLQQLGKGNF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L902 | REIEILKSLQH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L905 | EILKSLQHDNI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L927 | RRNLRLIMEYL | 2 | Mus musculus, Rattus norvegicus | L927 | RRNLKLIMEYL | 1 | Homo sapiens | L932 | LIMEYLPYGSL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L967 | KGMEYLGTKRY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L983 | ATRNILVENEN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M929 | NLRLIMEYLPY | 2 | Mus musculus, Rattus norvegicus | M929 | NLKLIMEYLPY | 1 | Homo sapiens | N678 | NVCAKNILLIR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N981 | DLATRNILVEN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | P933 | IMEYLPYGSLR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Q626 | ENILVQEFVKF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Q853 | HLKFLQQLGKG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Q854 | LKFLQQLGKGN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R980 | RDLATRNILVE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S633 | FVKFGSLDTYL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S862 | KGNFGSVEMCR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S936 | YLPYGSLRDYL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T555 | SLGQGTFTKIF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T557 | GQGTFTKIFKG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V629 | LVQEFVKFGSL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V863 | GNFGSVEMCRY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V911 | QHDNIVKYKGV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y931 | RLIMEYLPYGS | 2 | Mus musculus, Rattus norvegicus | Y931 | KLIMEYLPYGS | 1 | Homo sapiens | Y934 | MEYLPYGSLRD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |